In ADAM9‐silenced prostate cancer cells, the expression levels of integrin β1 was up‐regulated, whereas the activity of integrin β1 at cell surface was damaged and the formation of focal adhesions was delayed, probably explaining the reduction in cell adhesion and migration [43]. Here, ADAM9 is linked to prostate carcinoma.